» Articles » PMID: 11499564

Role of Proteinuria Reduction in the Progression of IgA Nephropathy

Overview
Journal Ren Fail
Publisher Informa Healthcare
Date 2001 Aug 14
PMID 11499564
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Unlabelled: Proteinuria has been shown to play a causal role in the progression towards ESRD of IgA nephropathy (IgAN). We demonstrated that steroids are effective in reducing proteinuria and preserving renal function.

Aim: to evaluate the long-term effect of steroids in IgAN patients (6th year evaluation) and better clarify the role of proteinuria reduction in slowing down the progression.

Methods: multicenter randomized controlled trial of 86 adult IgAN patients with serum creatinine < or = 1.5 mg/ dL and moderate proteinuria. They received either supportive therapy or methylprednisolone 1-g i.v. for three days at months 1, 3, and 5, plus oral prednisone (0.5 mg/kg every other day for six months).

Results: Proteinuria significantly decreased in the treated patients (from 2.0+/-0.60 g/24 h at baseline to 1.0+/-0.68 g/24 h at six months) and remained stable till the 6th year (0.67+/-0.5 g/24 h), it slightly decreased in the control group. Six-year renal survival was significantly better in the steroid than in the control group: 9 patient (20.9%) in the steroid group and 15 (34.8%) in the control group reached the primary end-point of a 50% increase in serum creatinine from baseline. Five controls and none of the steroid-treated patients started dialysis. Steroid-treated patients did not experience any major side effects during follow-up.

Conclusions: Steroids significantly reduce proteinuria and protect against renal function deterioration in IgAN patients. Early reduction of proteinuria could also be marker of a persistent reduction in its levels over time and of a better outcome in the long term.

Citing Articles

Immunosuppressants or corticosteroids compared with supportive therapy: a systematic review and meta-analysis on the efficacy and safety for IgA nephropathy treatment.

Feng Q, Xiong Y, Wang J, Feng L Ann Transl Med. 2022; 10(6):355.

PMID: 35433980 PMC: 9011262. DOI: 10.21037/atm-22-1028.


Association of Treatment Effects on Early Change in Urine Protein and Treatment Effects on GFR Slope in IgA Nephropathy: An Individual Participant Meta-analysis.

Inker L, Heerspink H, Tighiouart H, Chaudhari J, Miao S, Diva U Am J Kidney Dis. 2021; 78(3):340-349.e1.

PMID: 33775708 PMC: 8384669. DOI: 10.1053/j.ajkd.2021.03.007.


Efficacy and Safety of Immunosuppressive Monotherapy Agents for IgA Nephropathy: A Network Meta-Analysis.

Han S, Yao T, Lu Y, Chen M, Xu Y, Wang Y Front Pharmacol. 2021; 11:539545.

PMID: 33551793 PMC: 7862876. DOI: 10.3389/fphar.2020.539545.


Immunosuppressive agents for treating IgA nephropathy.

Natale P, Palmer S, Ruospo M, Saglimbene V, Craig J, Vecchio M Cochrane Database Syst Rev. 2020; 3:CD003965.

PMID: 32162319 PMC: 7066485. DOI: 10.1002/14651858.CD003965.pub3.


Efficacy and safety of immunosuppressive treatment in IgA nephropathy: a meta-analysis of randomized controlled trials.

Zhang Z, Yang Y, Jiang S, Li W BMC Nephrol. 2019; 20(1):333.

PMID: 31455248 PMC: 6710882. DOI: 10.1186/s12882-019-1519-3.